Distribution of values computed from the unequal variance test in patients with estrogen receptor (ER)-negative and ER-positive tumors

Gene expressions were compared between ER-negative tumors that had pathologic complete response and those that had a lesser response to preoperative chemotherapy. The resulting values for all comparisons were modeled as beta-uniform mixture. The straight line indicates the contribution of the uniform component, and the curved line is the fitted beta-distribution from the observed values. Deviation above the straight line indicates values that may represent true discovery. Distribution of values in patients with ER-positive tumors.<p><b>Copyright information:</b></p><p>Taken from "Evaluation of biological pathways involved in chemotherapy response in breast cancer"</p><p>http://breast-cancer-research.com/content/10/2/R37</p><p>Breast Cancer Research : BCR 2008;10(2):R37-R37.</p><p>Published online 29 Apr 2008</p><p>PMCID:PMC2397539.</p><p></p

Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses-0

<p><b>Copyright information:</b></p><p>Taken from "Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses"</p><p>http://www.biomedcentral.com/1471-2105/9/149</p><p>BMC Bioinformatics 2008;9():149-149.</p><p>Published online 15 Mar 2008</p><p>PMCID:PMC2292140.</p><p></p

Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses-1

<p><b>Copyright information:</b></p><p>Taken from "Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses"</p><p>http://www.biomedcentral.com/1471-2105/9/149</p><p>BMC Bioinformatics 2008;9():149-149.</p><p>Published online 15 Mar 2008</p><p>PMCID:PMC2292140.</p><p></p

Additional file 1: Table S1. of Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

List of authorities the survey methodology was compliant with at the time of survey administration. (DOCX 16 kb

Gene set enrichment results for estrogen receptor-negative breast tumors

Running enrichment scores (RESs) and the location of each probe set within the complete rank-ordered gene list for each gene set. The dotted line on the left indicates the position of the maximum RES, and the dotted line on the right indicates the zero position of the ranking metric score. Proliferation set (probe set n = 74). Genomic grade index (probe set n = 242). E2F3 pathway (probe set n = 173). Heat maps corresponding to these plots are provided in Supplementary Figure 1. pCR, pathologic complete response; RD, residual disease.<p><b>Copyright information:</b></p><p>Taken from "Evaluation of biological pathways involved in chemotherapy response in breast cancer"</p><p>http://breast-cancer-research.com/content/10/2/R37</p><p>Breast Cancer Research : BCR 2008;10(2):R37-R37.</p><p>Published online 29 Apr 2008</p><p>PMCID:PMC2397539.</p><p></p

Supplementary Figures S5-S6 from Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer

Supplementary Figures S5-S6 from Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cance

Additional file 2: Figure S1. of Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

Survey questionnaire

Gene set enrichment results for estrogen receptor (ER)-positive breast tumors

Results are presented as in Figure 2. Proliferation set. Genomic grade index. ER-associated genes (probe set n = 201). Mutant p53 gene signature (probe set n = 25). Heat maps corresponding to these plots are provided in Supplementary Figure 2. pCR, pathologic complete response; RD, residual disease.<p><b>Copyright information:</b></p><p>Taken from "Evaluation of biological pathways involved in chemotherapy response in breast cancer"</p><p>http://breast-cancer-research.com/content/10/2/R37</p><p>Breast Cancer Research : BCR 2008;10(2):R37-R37.</p><p>Published online 29 Apr 2008</p><p>PMCID:PMC2397539.</p><p></p

Supplementary Data from Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers

Supplementary Figures S1-S5; Supplementary Methods; Supplementary Tables S1-S6.</p

CCR Translation on this Article from Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

CCR Translation on this Article from Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Arra